# US Diabetic Retinopathy Market > US Diabetic Retinopathy Market Research Report: Size, Share, Trend Analysis By Types (Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR), By Treatment (Pharmacological Therapies, Laser Treatment, Surgery) and By End Users (Hospitals & Clinics, Ophthalmology Centers, Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.56% - **2024:** $ 1,740 Million - **2025:** $ 1,854.14 Million - **2035:** $ 3,500 Million - **Key Players:** Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Alcon (CH), Pfizer (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE) **Report ID:** MRFR/MED/14516-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** August 07, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-diabetic-retinopathy-market-16043 --- ## Market Summary ## **US Diabetic Retinopathy Market Overview** As per MRFR analysis, the US Diabetic Retinopathy Market Size was estimated at 1.81 (USD Billion) in 2023. The US Diabetic Retinopathy Market Industry is expected to grow from 2(USD Billion) in 2024 to 4 (USD Billion) by 2035. The US Diabetic Retinopathy Market CAGR (growth rate) is expected to be around 6.504% during the forecast period (2025 - 2035). ### **Key US Diabetic Retinopathy Market Trends Highlighted** The US Diabetic Retinopathy Market is seeing significant trends driven by the increasing prevalence of diabetes and a growing awareness of eye health among patients. One of the key market drivers is the rising number of diabetes cases, which has led to a proportional increase in diabetic retinopathy. As per the Centers for Disease Control and Prevention (CDC), millions of Americans are diagnosed with diabetes, resulting in more individuals at risk for diabetic eye diseases. This uptick in prevalence boosts demand for early screening and effective treatment options, leading to advancements in retinal imaging technology and laser therapy, making them pivotal in the market. Opportunities in the US Diabetic Retinopathy Market can be tapped into through innovations in telemedicine and digital health solutions. The COVID-19 pandemic highlighted the need for remote healthcare services, and companies are exploring telehealth platforms to facilitate patient screenings and consultations for diabetic retinopathy. This could expand access to care, especially for those in rural areas who may face barriers to visiting ophthalmologists or retina specialists. Recent trends also show an increase in the adoption of pharmacotherapy for managing diabetic retinopathy, including anti-VEGF injections and steroid implants. Furthermore, education efforts aimed at both healthcare providers and patients about the importance of regular eye examinations are gaining traction. The combination of technological advancements and increased awareness among patients is effectively shaping the landscape of the US Diabetic Retinopathy Market, creating an environment that encourages both treatment and prevention. As these developments continue to unfold, they are likely to redefine best practices in managing this prevalent condition. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Diabetic Retinopathy Market Drivers** ### **Increasing Prevalence of Diabetes in the United States** The US Diabetic Retinopathy Market Industry is significantly driven by the increasing prevalence of diabetes, which is a leading cause of diabetic retinopathy. According to the Centers for Disease Control and Prevention (CDC), approximately 37 million Americans had diabetes in 2020, and this figure is anticipated to rise by about 54% by 2030. This increase in diabetes cases directly correlates to a higher incidence of diabetic retinopathy, as nearly one-third of adults with diabetes are estimated to have some stage of diabetic retinopathy. Organizations such as the American Diabetes Association are focused on awareness and prevention strategies, further emphasizing the need for timely screening and treatment, which is expected to boost the market for diabetic retinopathy interventions. The projections indicate a growing user base, which is vital for the US Diabetic Retinopathy Market Industry's growth. ### **Advancements in Medical Technology** Technological advancements in diagnostic and therapeutic devices for diabetic retinopathy are a significant driver for the US Diabetic Retinopathy Market Industry. Innovations such as Optical Coherence Tomography (OCT) and artificial intelligence-based diagnostic tools are revolutionizing the early detection and treatment of this condition. According to the Food and Drug Administration (FDA), over 100 new devices for the diagnosis and treatment of ocular conditions have been approved in recent years. Such advancements provide practitioners with better tools for intervention, which can lead to improved patient outcomes and greater market growth. The increase in FDA approvals signals a vibrant innovation landscape, promising a robust future for the US Diabetic Retinopathy Market Industry. ### **Rising Awareness and Screening Programs** There is a growing awareness about diabetic retinopathy and the importance of regular screenings in the US, significantly impacting the US Diabetic Retinopathy Market Industry. Various health organizations, including the National Eye Institute, have launched awareness campaigns to educate both patients and healthcare providers on the need for routine eye exams for diabetic patients. As a result, screening rates have recently increased, with reports indicating that about 73% of diabetic patients received eye examinations each year, a substantial rise from 64% a decade ago. This increase in awareness directly correlates with market demand for diagnostic solutions and treatment options for diabetic retinopathy, fostering a conducive environment for industry growth. ## **US Diabetic Retinopathy Market Segment Insights** ### **Diabetic Retinopathy Market Type Insights** The US Diabetic Retinopathy Market is categorized into various types, with the two primary types being Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). Non-Proliferative Diabetic Retinopathy is characterized by the onset of retinal changes due to diabetes, initially presenting with mild symptoms but potentially leading to more severe sight-related issues if not treated. This type accounts for a majority holding in the overall diabetic retinopathy cases, making early detection and management crucial for preventing progression to the more advanced stage. It is often asymptomatic in the early stages, which presents a challenge for diagnosis; hence, regular screenings are vital for individuals with diabetes. Proliferative Diabetic Retinopathy, on the other hand, represents a more advanced stage where abnormal blood vessels grow on the retina, which increases the risk of vision loss significantly if intervention is not performed promptly. PDR tends to have a severe impact on an individual’s quality of life and requires more complicated treatment options, such as laser therapy and injections, which adds pressure on healthcare resources. The prevalence of both types is a direct reflection of the increasing cases of diabetes across the United States, with millions affected. Factors such as an aging population, rising obesity rates, and sedentary lifestyles contribute to this trend, thus creating a growing demand for therapeutic interventions to manage and treat these conditions. The awareness of diabetic retinopathy in the healthcare community is also evolving, with professionals emphasizing the importance of screening and education around diabetic complications. In summary, understanding the nuances of NPDR and PDR is essential for addressing the broader challenges posed by diabetic retinopathy within the US, particularly as the market aligns itself to provide better diagnostics and treatments tailored to these specific types. This segment holds significant potential for advancements, as continuous research and development, alongside efforts to raise public awareness, shape patient outcomes in meaningful ways. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Diabetic Retinopathy Market Treatment Insights** The Treatment segment of the US Diabetic Retinopathy Market plays a critical role in managing this chronic disease, which affects a significant portion of the population. This segmentation comprises various approaches, including Pharmacological Therapies, Laser Treatment, and Surgery. Pharmacological Therapies, which often utilize anti-VEGF injections, are pivotal for halting disease progression and preserving vision. They are widely adopted due to their effectiveness and have become a standard intervention for patients with diabetic retinopathy. Laser Treatment is well-established as an efficient method to manage retinal complications, leveraging precision to target affected areas and reduce the risk of severe vision loss. Its significance is underscored by its ability to provide immediate intervention that is vital in advanced stages of the disease. Lastly, Surgery is crucial for cases where other treatments are ineffective, demonstrating advancements in techniques like vitrectomy that have improved outcomes for patients facing severe visual impairment. The strong growth of this segment reflects the increasing prevalence of diabetes in the US, coupled with a rising awareness of diabetic retinopathy, presenting substantial opportunities for innovative treatments and improved patient care. ### **Diabetic Retinopathy Market End User Insights** The End User segment of the US Diabetic Retinopathy Market includes key players such as Hospitals and Clinics, Ophthalmology Centers, and Research Institutes, each playing a pivotal role in the diagnosis and treatment of diabetic retinopathy. Hospitals and Clinics represent a substantial component, offering comprehensive services and specialized care for patients suffering from diabetic-related vision issues. Ophthalmology Centers focus specifically on eye-related disorders, providing advanced diagnostic tools and therapeutic interventions that cater to a growing patient population. Research Institutes contribute significantly to this landscape by facilitating innovation and conducting clinical trials that drive the development of cutting-edge therapies and technologies for diabetic eye diseases. The increasing prevalence of diabetes in the US substantially influences demand across these segments, as effective management of diabetic retinopathy becomes crucial to preserving vision. Additionally, advancements in medical technology and increased awareness about early diagnosis further bolster the importance of these facilities in providing both treatment and patient education. ## **US Diabetic Retinopathy Market Key Players and Competitive Insights** The US Diabetic Retinopathy Market has grown significantly in recent years, driven by the increasing prevalence of diabetes and the resulting demand for effective treatment options. This market encompasses a variety of therapeutic solutions, including pharmaceuticals and surgical interventions, aimed at addressing the vision complications associated with diabetic retinopathy. The competitive landscape is characterized by the presence of numerous players, each contributing to innovations in diagnostics, treatment modalities, and technologies that enhance patient outcomes. The landscape is influenced not only by established pharmaceutical giants but also by emerging biotechnology companies focusing on niche markets within the diabetic retinopathy space. As competition intensifies, companies are emphasizing product differentiation, establishing strategic partnerships, and investing in research to ensure a foothold in this lucrative market. Teva Pharmaceutical Industries has carved out a notable position within the US Diabetic Retinopathy Market through its extensive portfolio and commitment to accessibility. The company's strengths lie in its comprehensive range of generic and specialty medications, providing affordable treatment alternatives to patients. Teva is recognized for its focus on research and development, allowing it to adapt and expand its treatment options in response to evolving market needs. Furthermore, its established distribution channels ensure broad market reach, facilitating easier access to its products for healthcare providers and patients alike. Teva's operational efficiencies and focus on cost management help maintain competitive pricing, which is crucial in the context of a market where affordability is a significant factor in treatment selection. Genentech, a leader in the US Diabetic Retinopathy Market, is renowned for its innovative biotechnology solutions, particularly in developing novel therapies aimed at preventing vision loss in diabetic patients. The company's flagship products include anti-VEGF agents that have transformed the treatment landscape for diabetic retinopathy, providing effective options that enhance visual acuity and slow disease progression. Genentech's robust presence in the market is underpinned by a strong R&D pipeline, consistently delivering groundbreaking advancements that address unmet medical needs. The company has also engaged in strategic partnerships and collaborations with academic institutions and other firms to expand its product offerings and accelerate clinical development. Mergers and acquisitions have played a key role in strengthening Genentech's market position, enabling the integration of diversified therapeutic capabilities. The company’s commitment to patient support programs further reinforces its standing in the US, making it a trusted name among healthcare professionals and patients navigating the challenges posed by diabetic retinopathy. ### **Key Companies in the US Diabetic Retinopathy Market Include** ## **US Diabetic Retinopathy Market Industry Developments** The US Diabetic Retinopathy Market has seen significant developments recently, particularly with the increasing focus on innovative treatment options to address the growing patient population suffering from this condition. Companies such as Regeneron Pharmaceuticals and Aerie Pharmaceuticals have been pivotal in advancing therapies, with Regeneron’s Eylea continuing to dominate the market due to its effectiveness in treating diabetic macular edema. In September 2023, Genentech announced an expansion of its geographic footprint for the Lucentis therapy, further enhancing patient access. Additionally, Novartis launched an initiative aimed at increasing awareness about diabetic retinopathy among healthcare providers and patients alike. In terms of mergers and acquisitions, Alimera Sciences announced in August 2023 its intention to acquire new therapeutic assets to strengthen its portfolio in this market. Growth metrics indicate an expanding market valuation for companies like Pfizer and Amgen, driven by increased investments in Research and Development and a focus on personalized medicine. Over the past few years, initiatives to enhance screening and early intervention, particularly during the COVID-19 pandemic when many patients deferred care, have highlighted underlying challenges and opportunities to improve outcomes in diabetic retinopathy management in the US. ## **US Diabetic Retinopathy Market Segmentation Insights** ### **Diabetic Retinopathy Market Type Outlook** ### **Diabetic Retinopathy Market Treatment Outlook** ### **Diabetic Retinopathy Market End User Outlook** ## Market Drivers ### Rising Prevalence of Diabetes The increasing incidence of diabetes in the US is a primary driver for the diabetic retinopathy market. According to the Centers for Disease Control and Prevention (CDC), approximately 34.2 million people in the US have diabetes, which translates to about 10.5% of the population. This growing diabetic population is likely to lead to a corresponding rise in diabetic retinopathy cases, as the condition is a common complication of diabetes. As awareness of the disease and its complications increases, healthcare providers are expected to focus more on screening and treatment options, thereby expanding the diabetic retinopathy market. Furthermore, the economic burden associated with diabetes management, estimated at $327 billion annually, underscores the need for effective interventions in the diabetic retinopathy market. ### Increased Awareness and Education There is a growing emphasis on awareness and education regarding diabetic retinopathy, which serves as a crucial driver for the diabetic retinopathy market. Public health campaigns and initiatives by organizations such as the American Diabetes Association aim to educate both patients and healthcare professionals about the risks associated with diabetic retinopathy. This heightened awareness is likely to lead to earlier diagnosis and treatment, ultimately improving patient outcomes. Furthermore, educational programs targeting at-risk populations can enhance understanding of the importance of regular eye examinations. As more individuals become informed about the potential complications of diabetes, the demand for screening and treatment services in the diabetic retinopathy market is expected to rise. ### Advancements in Treatment Modalities Innovations in treatment options for diabetic retinopathy are significantly influencing the diabetic retinopathy market. Recent developments in pharmacotherapy, including anti-VEGF (vascular endothelial growth factor) agents, have shown promising results in managing the disease. The introduction of these therapies has the potential to improve patient outcomes and reduce the risk of vision loss. Additionally, laser treatments and surgical interventions continue to evolve, offering more effective solutions for patients. The market for these advanced treatments is projected to grow, with estimates suggesting a compound annual growth rate (CAGR) of around 6.5% over the next several years. As healthcare providers adopt these new modalities, the diabetic retinopathy market is likely to expand, driven by the demand for improved therapeutic options. ### Integration of Digital Health Solutions The integration of digital health solutions into the management of diabetic retinopathy is emerging as a key driver for the diabetic retinopathy market. Telehealth platforms and mobile health applications are increasingly being utilized to facilitate remote monitoring and consultations for patients with diabetes. These technologies enable healthcare providers to track disease progression and offer timely interventions, which can be particularly beneficial for those in underserved areas. The convenience and accessibility of digital health solutions may lead to increased patient engagement and adherence to treatment plans. As the adoption of these technologies continues to grow, the diabetic retinopathy market is likely to benefit from enhanced patient management and improved clinical outcomes. ### Regulatory Support for Innovative Therapies Regulatory bodies in the US are increasingly supportive of innovative therapies for diabetic retinopathy, which is likely to bolster the diabetic retinopathy market. The Food and Drug Administration (FDA) has streamlined the approval process for new treatments, facilitating quicker access to novel therapies for patients. This regulatory environment encourages pharmaceutical companies to invest in research and development, leading to a wider array of treatment options. The approval of new drugs and technologies can stimulate market growth, as healthcare providers are more inclined to adopt effective solutions that have received regulatory endorsement. Consequently, the diabetic retinopathy market may experience significant expansion as new therapies become available to clinicians and patients. ## Future Outlook The [Diabetic Retinopathy Market](https://www.marketresearchfuture.com/reports/diabetic-retinopathy-market-5792) is projected to grow at a 6.56% CAGR from 2025 to 2035, driven by advancements in treatment technologies and increasing prevalence of diabetes. **New opportunities:** - Development of AI-driven diagnostic tools for early detection Expansion of telemedicine services for remote patient monitoring Investment in innovative drug delivery systems for sustained treatment By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Type: Non-Proliferative Diabetic Retinopathy (Dominant) vs. Proliferative Diabetic Retinopathy (Fastest-Growing) In the US diabetic retinopathy market, Non-Proliferative Diabetic Retinopathy (NPDR) represents the dominant segment, characterized by its higher prevalence among patients compared to Proliferative Diabetic Retinopathy (PDR). NPDR accounts for a significant share of the overall market, driven by the increasing number of diabetes cases leading to early-stage retinal complications. On the other hand, PDR is emerging rapidly as a concern due to its severe nature and potential for vision loss, thus capturing attention from both healthcare providers and patients alike. Growth trends in this segment are primarily influenced by the aging population and rising diabetes incidence rates, which are expected to continue driving NPDR diagnosis and management. Additionally, advancements in treatment options and technologies are facilitating better patient outcomes in both NPDR and PDR. As awareness increases regarding diabetic complications, demand for timely interventions is rising, making PDR the fastest-growing segment, as more patients seek treatments to prevent irreversible vision impairment. Non-Proliferative Diabetic Retinopathy (Dominant) vs. Proliferative Diabetic Retinopathy (Fastest-Growing) Non-Proliferative Diabetic Retinopathy (NPDR) is characterized by the presence of microaneurysms and retinal hemorrhages without neovascularization, making it the leading stage of diabetic retinopathy. It is primarily diagnosed in patients with diabetes, leading to visual impairment if left untreated. This segment holds a robust market position due to its widespread recognition and earlier diagnosis among healthcare professionals. In contrast, Proliferative Diabetic Retinopathy (PDR) represents a more advanced stage, marked by significant retinal vascular changes and the potential for severe vision loss. Its rapid growth is driven by increased awareness of diabetic complications and the evolving landscape of treatment options, indicating a shift in focus towards managing advanced retinal diseases. ### By Treatment: Pharmacological Therapies (Largest) vs. Laser Treatment (Fastest-Growing) In the US diabetic retinopathy market, the share distribution among treatment modalities reveals that pharmacological therapies hold the majority, largely due to the increasing prevalence of diabetes and the availability of innovative drug formulations. Laser treatment follows as a significant option, commonly utilized in cases requiring urgent intervention to prevent further vision loss. Surgery, while essential in advanced cases, remains a smaller segment in terms of overall market share. Growth trends indicate that pharmacological therapies are bolstered by continual advancements in medication efficacy and patient adherence. Laser treatment is rapidly gaining traction as technology improves, allowing for less invasive procedures with quicker recovery times. The rise in diabetic population and increased awareness about preventive treatments are leading to a surge in all treatment segments, particularly favoring the fastest adaptations like laser therapy. Pharmacological Therapies (Dominant) vs. Laser Treatment (Emerging) Pharmacological therapies are characterized by their dominant role in managing diabetic retinopathy, offering effective solutions that prevent disease progression. These therapies leverage innovative drugs that target underlying pathophysiological aspects of the condition. The enduring popularity of these treatments can be attributed to their supportive clinical research and tangible success in improving patient outcomes. Conversely, laser treatment is emerging rapidly, providing effective options that cater to immediate and severe cases. With technological advancements in laser capabilities, this treatment is becoming increasingly streamlined, offering benefits like reduced side effects and enhanced precision. Together, these treatment modalities highlight the robust landscape of interventions available in the market, meeting varying patient needs. ### By End User: Hospitals & Clinics (Largest) vs. Ophthalmology Centers (Fastest-Growing) In the US diabetic retinopathy market, hospitals and clinics hold the largest share, significantly contributing to the overall treatment landscape. These facilities are equipped with comprehensive resources and specialized personnel, making them the primary destination for patients requiring management of diabetic retinopathy. On the other hand, ophthalmology centers are emerging as a rapidly expanding segment, offering tailored services and advanced technology fostering efficient treatment outcomes. The growth trends within this segment can be attributed to various factors, including an increasing prevalence of diabetes and the associated complications like diabetic retinopathy. Moreover, advancements in diagnostic technologies and treatment modalities at ophthalmology centers are positioning them as notable players in the market. The collaboration between hospitals and specialty centers also contributes to enhancing patient care pathways and overall awareness of diabetic eye diseases. Hospitals & Clinics (Dominant) vs. Ophthalmology Centers (Emerging) Hospitals and clinics are pivotal in the management of diabetic retinopathy, providing patients with access to multidisciplinary care and a range of treatment options. These facilities often integrate various specialties, allowing for comprehensive patient assessments and interventions. Conversely, ophthalmology centers focus on providing specialized care, utilizing cutting-edge technology and advanced techniques to address diabetic retinopathy more effectively. This specialized focus makes them an emerging choice for patients seeking expedited and targeted treatment solutions. The dynamics between these two segment values are vital, as hospitals rely on streamlined collaboration with ophthalmology centers to enhance patient outcomes and optimize treatment protocols. ## Competitive Benchmarking The diabetic retinopathy market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and advancements in treatment modalities. Key players such as Novartis (CH), Regeneron Pharmaceuticals (US), and Bayer (DE) are at the forefront, each adopting distinct strategies to enhance their market positioning. Novartis (CH) focuses on innovation through its robust pipeline of therapies, while Regeneron Pharmaceuticals (US) emphasizes partnerships to expand its reach and enhance its product offerings. Bayer (DE) is actively pursuing regional expansion, particularly in underserved markets, which collectively shapes a competitive environment that is both collaborative and competitive.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Novartis (CH) and Regeneron Pharmaceuticals (US) suggests a trend towards consolidation, as these firms leverage their resources to gain competitive advantages. In October Regeneron Pharmaceuticals (US) announced a strategic partnership with a leading telehealth provider to enhance patient access to diabetic retinopathy screenings. This move is significant as it aligns with the growing trend of digital health solutions, potentially increasing early detection rates and improving patient outcomes. Such initiatives may also position Regeneron as a leader in integrating technology with traditional healthcare practices. In September Bayer (DE) launched a new initiative aimed at increasing awareness and education around diabetic retinopathy in rural areas. This initiative is crucial, as it addresses the disparities in healthcare access, particularly in regions where patients may be unaware of the risks associated with the condition. By focusing on education, Bayer not only enhances its corporate social responsibility profile but also fosters brand loyalty among healthcare providers and patients alike. In November Novartis (CH) unveiled a groundbreaking therapy that utilizes AI to personalize treatment plans for diabetic retinopathy patients. This innovation is indicative of the broader trend towards digitalization and AI integration within the healthcare sector. By leveraging advanced technologies, Novartis is likely to differentiate itself in a competitive market, emphasizing the importance of innovation over traditional price-based competition. As of November the competitive trends in the diabetic retinopathy market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their service offerings. Looking ahead, competitive differentiation is expected to evolve, with a pronounced shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This evolution may ultimately lead to improved patient outcomes and a more sustainable healthcare ecosystem. ## Recent News & Developments The US Diabetic Retinopathy Market has seen significant developments recently, particularly with the increasing focus on innovative treatment options to address the growing patient population suffering from this condition. Companies such as Regeneron Pharmaceuticals and Aerie Pharmaceuticals have been pivotal in advancing therapies, with Regeneron’s Eylea continuing to dominate the market due to its effectiveness in treating diabetic macular edema. In September 2023, Genentech announced an expansion of its geographic footprint for the Lucentis therapy, further enhancing patient access. Additionally, Novartis launched an initiative aimed at increasing awareness about diabetic retinopathy among healthcare providers and patients alike. In terms of mergers and acquisitions, Alimera Sciences announced in August 2023 its intention to acquire new therapeutic assets to strengthen its portfolio in this market. Growth metrics indicate an expanding market valuation for companies like Pfizer and Amgen, driven by increased investments in Research and Development and a focus on personalized medicine. Over the past few years, initiatives to enhance screening and early intervention, particularly during the COVID-19 pandemic when many patients deferred care, have highlighted underlying challenges and opportunities to improve outcomes in diabetic retinopathy management in the US. ## Report Scope | MARKET SIZE 2024 | 1740.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1854.14(USD Million) | | MARKET SIZE 2035 | 3500.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.56% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Alcon (CH), Pfizer (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE) | | Segments Covered | Type, Treatment, End User | | Key Market Opportunities | Advancements in telemedicine and AI-driven diagnostics enhance access to diabetic retinopathy screening. | | Key Market Dynamics | Technological advancements in treatment options drive competitive dynamics in the diabetic retinopathy market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US diabetic retinopathy market in 2024?** A: The market valuation was $1740.0 Million in 2024. **Q: What is the projected market valuation for the US diabetic retinopathy market by 2035?** A: The projected valuation for 2035 is $3500.0 Million. **Q: What is the expected CAGR for the US diabetic retinopathy market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 6.56%. **Q: Which segments are included in the US diabetic retinopathy market?** A: The segments include Type, Treatment, and End User. **Q: What are the projected valuations for Non-Proliferative Diabetic Retinopathy (NPDR) by 2035?** A: The projected valuation for NPDR is between $1040.0 Million and $2100.0 Million. **Q: How does the market for Proliferative Diabetic Retinopathy (PDR) compare to NPDR?** A: The projected valuation for PDR ranges from $700.0 Million to $1400.0 Million, indicating a smaller market than NPDR. **Q: What are the key treatment options available in the US diabetic retinopathy market?** A: Key treatment options include Pharmacological Therapies, Laser Treatment, and Surgery. **Q: What is the projected valuation for Laser Treatment by 2035?** A: The projected valuation for Laser Treatment is between $700.0 Million and $1300.0 Million. **Q: Which end users are expected to drive the US diabetic retinopathy market?** A: End users include Hospitals & Clinics, Ophthalmology Centers, and Research Institutes. **Q: What is the projected valuation for Hospitals & Clinics by 2035?** A: The projected valuation for Hospitals & Clinics is between $800.0 Million and $1600.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-diabetic-retinopathy-market-16043*